La brecha de evidencia sobre la seguridad a largo plazo de las nuevas terapias tópicas no esteroideas en la dermatitis atópica pediátrica

Autores/as

  • Isabela Santos Conde Secretaria Municipal de Saúde do Rio de Janeiro (SMS-RJ) Autor
  • Júlia Pessanha Chequer Universidade Iguaçu (Campus V - Itaperuna) Autor
  • Ana Carolina de Andrade Alves Universidade Estadual do Rio de Janeiro (UERJ) Autor
  • Luana Livelli Becker Universidade Federal do Acre (UFAC) Autor

DOI:

https://doi.org/10.5281/zenodo.23807703

Palabras clave:

Dermatitis Atópica. Niño. Seguridad de Medicamentos. Tratamiento Farmacológico. Farmacovigilancia.

Resumen

La dermatitis atópica pediátrica suele requerir tratamientos tópicos repetidos, por lo que es esencial diferenciar la buena tolerabilidad observada en ensayos clínicos de la seguridad demostrada tras una exposición acumulada prolongada. El objetivo de esta revisión fue analizar críticamente la evidencia de seguridad del crisaborol, roflumilast, ruxolitinib, tapinarof, delgocitinib y difamilast en niños y lactantes. Se realizó una revisión narrativa mediante búsquedas en SciSpace y verificación complementaria de estudios publicados, guías clínicas y documentos regulatorios, actualizada hasta octubre de 2026. Se consideraron ensayos aleatorizados, extensiones abiertas, investigaciones farmacocinéticas y síntesis bibliográficas. La evidencia incluye seguimientos de 48 a 60 semanas, estudios de uso máximo y cohortes de lactantes, aunque algunos resultados proceden de muestras pequeñas o poblaciones de edades mixtas (Bissonnette et al., 2025; Igarashi et al., 2026; Saeki et al., 2026). Un metanálisis en red de 15 ensayos, con 3.994 participantes pediátricos, indicó tolerabilidad general a corto plazo, pero pocas comparaciones directas entre tratamientos (Yang et al., 2026). Se concluye que los resultados favorables durante aproximadamente un año no excluyen acontecimientos raros, efectos de latencia prolongada ni riesgos derivados de exposiciones plurianuales; se requieren estudios longitudinales y farmacovigilancia pediátrica estructurada (Davis et al., 2026; Chokshi et al., 2026).

Referencias

BISSONNETTE et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. Journal of the American Academy of Dermatology, 93(3), 707–714, 2025. DOI: https://doi.org/10.1016/j.jaad.2025.05.1391.

CHOKSHI et al. Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology, 2026. DOI: https://doi.org/10.1111/pde.70298.

DAVIS et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology, 95(1), 121.e1–121.e26, 2026. DOI: https://doi.org/10.1016/j.jaad.2026.02.113.

EICHENFIELD et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 77(4), 641–649.e5, 2017. DOI: https://doi.org/10.1016/j.jaad.2017.06.010.

EICHENFIELD et al. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study. American Journal of Clinical Dermatology, 24(4), 623–635, 2023. DOI: https://doi.org/10.1007/s40257-023-00780-w.

EICHENFIELD et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. Journal of the American Academy of Dermatology, 93(3), 689–698, 2025. DOI: https://doi.org/10.1016/j.jaad.2025.05.1385.

EICHENFIELD et al. Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). Pediatric Dermatology, 43(3), 642–649, 2026. DOI: https://doi.org/10.1111/pde.70177.

GARG et al. Topical Janus Kinase Inhibitors for Atopic Dermatitis in Children Under 12 Years: A Systematic Review. The Journal of Pediatric Academy, 2026. DOI: https://doi.org/10.4274/jpea.2026.514.

GILLESPIE et al. Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis. Current Opinion in Pediatrics, 38(4), 382–388, 2026. DOI: https://doi.org/10.1097/MOP.0000000000001580.

IGARASHI et al. Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period. Journal of Cutaneous Immunology and Allergy, 9, Artigo 17307, 2026. DOI: https://doi.org/10.3389/jcia.2026.17307.

JOYCE et al. Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study. American Journal of Clinical Dermatology, 27, 841–849, 2026. DOI: https://doi.org/10.1007/s40257-026-01043-0.

NAKAGAWA et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. Journal of the American Academy of Dermatology, 2021. DOI: https://doi.org/10.1016/j.jaad.2021.06.014.

NAKAGAWA et al. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study. Allergology International, 73(1), 137–142, 2024. DOI: https://doi.org/10.1016/j.alit.2023.04.003.

NATIONAL LIBRARY OF MEDICINE. VTAMA — tapinarof cream: prescribing information (atualização 2025). DailyMed, 2025. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9309d20f-8cd4-4c96-93fa-7f730e83c7ab. Acesso em: 28 out. 2026.

NATIONAL LIBRARY OF MEDICINE. ZORYVE — roflumilast cream: prescribing information (atualização 2026). DailyMed, 2026a. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec1bb0d1-f38a-4080-831a-68791d1d1fdb. Acesso em: 28 out. 2026.

NATIONAL LIBRARY OF MEDICINE. OPZELURA — ruxolitinib cream: prescribing information (atualização de 30 jun. 2026). DailyMed, 2026b. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7. Acesso em: 28 out. 2026.

PAPP et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology, 88(5), 1008–1016, 2023. DOI: https://doi.org/10.1016/j.jaad.2022.09.060.

SAEKI et al. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. British Journal of Dermatology, 186(1), 40–49, 2022. DOI: https://doi.org/10.1111/bjd.20655.

SAEKI et al. A Phase 3, Long-Term, Open-Label Study of Difamilast Ointment to Evaluate Efficacy and Safety in Japanese Infants with Atopic Dermatitis. Dermatology and Therapy (Heidelberg), 16(1), 339–352, 2026. DOI: https://doi.org/10.1007/s13555-025-01581-1.

SCHLESSINGER et al. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology, 21(2), 275–284, 2020. DOI: https://doi.org/10.1007/s40257-020-00510-6.

SIEGFRIED et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatrics, 2016. DOI: https://doi.org/10.1186/s12887-016-0607-9.

SILVERBERG et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. Journal of the American Academy of Dermatology, 91(3), 457–465, 2024. DOI: https://doi.org/10.1016/j.jaad.2024.05.023.

SIMPSON et al. Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis, 37(1), 75–83, 2026. DOI: https://doi.org/10.1089/derm.2024.0418.

STEIN GOLD et al. A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 26(2), 275–289, 2025. DOI: https://doi.org/10.1007/s40257-024-00909-5.

YANG et al. Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Immunology, 17, 1906218, 2026. DOI: https://doi.org/10.3389/fimmu.2026.1906218.

Publicado

2026-10-30

Número

Sección

Artigos

Cómo citar

CONDE, Isabela Santos; CHEQUER, Júlia Pessanha; ALVES, Ana Carolina de Andrade; BECKER, Luana Livelli. La brecha de evidencia sobre la seguridad a largo plazo de las nuevas terapias tópicas no esteroideas en la dermatitis atópica pediátrica. Journal of Social Issues and Health Sciences (JSIHS), [S. l.], v. 3, n. 4, 2026. DOI: 10.5281/zenodo.23807703. Disponível em: https://ojs.thesiseditora.com.br/index.php/jsihs/article/view/739.. Acesso em: 18 nov. 2026.